Diuretic Effect Evaluation of Petroselinum Crispum (Parsley) in Hypertensive Patients
Schlüsselwörter
Abstrakt
Beschreibung
Parsley botanically known as Petroselinum crispum, belongs to the family Umbeliferae, originated from Mediterranean region however, it is cultivated almost throughout the world now-a-days. The plant has reported folkloric uses in different parts of the world; in Iran the seeds of the plant is used for different pharmacological effects including antimicrobial, kidney stones, digestive disorders etc., in Turkey the leaves of this plant is used to treat hypertension, diabetes and as a diuretic in Morocco the leaves are used for arterial hypertension, diabetes, high blood pressure and cardiac diseases in Spain the leaves of this plant are used to treat hypertension, diabetes, prostititis and anemia whereas in Serbia the leaves of the plant are used to treat urinary tract diseases and infections. Though the aforementioned literature supports the diuretic and anti-hypertensive potential of parsley however no in-vivo studies have been reported to establish its diuretic activity in human subjects. Some studies have reported diuretic activity for seed aqueous extract in rats. Still, to evaluate the effect in human subjects, an in-vivo phase-I clinical study is needed to support the pre-clinical in-vivo and in-vitro diuretic effects of this plant. Our study aims to investigate the diuretic and anti-hypertensive activity of parsley in hypertensive individuals currently using conventional medication.
Termine
| Zuletzt überprüft: | 02/29/2020 |
| Zuerst eingereicht: | 03/10/2018 |
| Geschätzte Einschreibung eingereicht: | 03/10/2018 |
| Zuerst veröffentlicht: | 03/15/2018 |
| Letztes eingereichtes Update: | 03/22/2020 |
| Letztes Update veröffentlicht: | 03/24/2020 |
| Tatsächliches Startdatum der Studie: | 02/28/2018 |
| Geschätztes primäres Abschlussdatum: | 12/30/2019 |
| Voraussichtliches Abschlussdatum der Studie: | 01/30/2020 |
Zustand oder Krankheit
Intervention / Behandlung
Other: Intervention Group
Other: Control Group
Phase
Armgruppen
| Arm | Intervention / Behandlung |
|---|---|
| Placebo Comparator: Control Group Patients in control group will be allowed to continue their conventional medications and with a placebo. | Other: Control Group Soft gelatin capsules will be filled with 1 gram of lactose (inert pharmaceutical ingredient) and will be administered to patients once daily. |
| Experimental: Intervention Group Patients in intervention group who would be taking their usual medications along with parsley in a convenient dosage form. | Other: Intervention Group Parsley herb, in fresh form will be obtained from the local market available. The herb will be properly washed with distilled water and dried properly for 10 to 15 days under shade in the lab. Soft gelatin capsules will be filled with parsley powder (dried herb) in amount normally recommended in daily routine (1g) will be administered to patients once daily. |
Zulassungskriterien
| Altersberechtigt für das Studium | 18 Years Zu 18 Years |
| Studienberechtigte Geschlechter | All |
| Akzeptiert gesunde Freiwillige | Ja |
| Kriterien | Inclusion Criteria: - Any male or female patients with hypertension and already using conventional medications i.e. antihypertensive drugs. The consent forms will be provided to the patients and only those patients which are willing to participate will be included in the study. Patients with more than 3 co-morbidities and at high-risk conditions will not be included in the study. Exclusion Criteria: - Geriatric, pregnant and lactating patients will not be included in the study. More important, patients on diuretic medications as well as diabetes, will also be excluded from the study. |
Ergebnis
Primäre Ergebnismaße
1. Change in baseline mean Blood pressure at day 7, day 14 and 21 [For observing any change in mean blood pressure, a blood pressure monitor will be used to determine any variation in blood pressure in millimeters of mercury (mm of Hg). A total of four readings will be taken at baseline day 0, day 7, day 14 and day 21.]
2. Change in baseline mean urinary output at day 7, day 14 and 21 [For observing any change in mean urinary output a total of four readings will be taken at baseline day 0, day 7, day 14 and day 21.]
